{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T00:58:42Z","timestamp":1774054722463,"version":"3.50.1"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1097\/ico.0b013e318292a79d","type":"journal-article","created":{"date-parts":[[2013,6,5]],"date-time":"2013-06-05T11:18:39Z","timestamp":1370431119000},"page":"1142-1148","source":"Crossref","is-referenced-by-count":12,"title":["The Inhibitory Effect of Thalidomide Analogue on Corneal Neovascularization in Rabbits"],"prefix":"10.1097","volume":"32","author":[{"given":"You Kyung","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung Kun","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-16-20210204","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/nature05249","article-title":". Corneal avascularity is due to soluble VEGF receptor-1.","volume":"443","author":"Ambati","year":"2006","journal-title":"Nature"},{"key":"R2-16-20210204","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/00055735-200108000-00002","article-title":". Corneal neovascularization.","volume":"12","author":"Chang","year":"2001","journal-title":"Curr Opin Ophthalmol"},{"key":"R3-16-20210204","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/00003226-198706040-00004","article-title":". Corneal neovascularization. Pathogenesis and inhibition.","volume":"6","author":"Epstein","year":"1987","journal-title":"Cornea"},{"key":"R4-16-20210204","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/00004397-198302310-00005","article-title":"Neovascularization of the cornea: current concepts of its pathogenesis.","volume":"23","author":"Klintworth","year":"1983","journal-title":"Int Ophthalmol Clin"},{"key":"R5-16-20210204","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.preteyeres.2006.09.002","article-title":"Ocular neovascularization: implication of endogenous angiogenic inhibitors and potential therapy.","volume":"26","author":"Zhang","year":"2007","journal-title":"Prog Retin Eye Res"},{"key":"R6-16-20210204","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1590\/S0001-37652007000300004","article-title":"The effects of the subconjunctival injection of bevacizumab (Avastin) on angiogenesis in the rat cornea.","volume":"79","author":"Barros","year":"2007","journal-title":"An Acad Bras Cienc"},{"key":"R7-16-20210204","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00417-007-0587-4","article-title":"Subconjunctival bevacizumab for corneal neovascularization.","volume":"245","author":"Erdurmus","year":"2007","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R8-16-20210204","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1038\/eye.2008.88","article-title":"Anti-VEGF therapy: comparison of current and future agents.","volume":"22","author":"Pieramici","year":"2008","journal-title":"Eye (Lond)"},{"key":"R9-16-20210204","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.survophthal.2012.01.007","article-title":". Corneal neovascularization: an anti-VEGF therapy review.","volume":"57","author":"Chang","year":"2012","journal-title":"Surv Ophthalmol"},{"key":"R10-16-20210204","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.preteyeres.2006.09.001","article-title":". Regulation of corneal angiogenesis in limbal stem cell deficiency.","volume":"25","author":"Ma","year":"2006","journal-title":"Prog Retin Eye Res"},{"key":"R11-16-20210204","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/ICO.0b013e3181ae91e3","article-title":"The effect of subconjunctival suramin on corneal neovascularization in rabbits.","volume":"29","author":"Lee","year":"2010","journal-title":"Cornea"},{"key":"R12-16-20210204","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/ICO.0b013e3181b1c82f","article-title":"The effect of subconjuctival combined treatment of bevacizumab and triamcinolone acetonide on corneal neovascularization in rabbits.","volume":"29","author":"Kang","year":"2010","journal-title":"Cornea"},{"key":"R13-16-20210204","doi-asserted-by":"crossref","first-page":"274","DOI":"10.3109\/02713680903528345","article-title":"The effect of curcumin on corneal neovascularization in rabbit eyes.","volume":"35","author":"Kim","year":"2010","journal-title":"Curr Eye Res"},{"key":"R14-16-20210204","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3341\/kjo.2010.24.4.230","article-title":"The effect of bevacizumab on corneal neovascularization in rabbits.","volume":"24","author":"Kim","year":"2010","journal-title":"Korean J Ophthalmol"},{"key":"R15-16-20210204","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/IAE.0b013e3181e46ad8","article-title":"The effect of methotrexate on corneal neovascularization in rabbits.","volume":"30","author":"Byun","year":"2011","journal-title":"Cornea"},{"key":"R16-16-20210204","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1084\/jem.173.3.699","article-title":". Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes.","volume":"173","author":"Sampaio","year":"1991","journal-title":"J Exp Med"},{"key":"R17-16-20210204","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/S1286-4579(02)01645-3","article-title":". Thalidomide in the treatment of leprosy.","volume":"4","author":"Teo","year":"2002","journal-title":"Microbes Infect"},{"key":"R18-16-20210204","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1046\/j.1365-2141.2003.03929.x","article-title":"Novel therapies for multiple myeloma.","volume":"120","author":"Hayashi","year":"2003","journal-title":"Br J Haematol"},{"key":"R19-16-20210204","doi-asserted-by":"crossref","first-page":"364","DOI":"10.2165\/00002018-199512060-00002","article-title":"Thalidomide: rationale for renewed use in immunological disorders.","volume":"12","author":"Schuler","year":"1995","journal-title":"Drug Saf"},{"key":"R20-16-20210204","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1136\/bmj.298.6671.432","article-title":". Treatment of resistant aphthous ulceration with thalidomide in patients positive for HIV antibody.","volume":"298","author":"Youle","year":"1989","journal-title":"BMJ"},{"key":"R21-16-20210204","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/00042560-199603010-00005","article-title":". The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M. tuberculosis infection.","volume":"11","author":"Klausner","year":"1996","journal-title":"J Acquir Immune Defic Syndr Hum Retrovirol"},{"key":"R22-16-20210204","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1056\/NEJM199204163261604","article-title":". Thalidomide for the treatment of chronic graft-versus-host disease.","volume":"326","author":"Vogelsang","year":"1992","journal-title":"N Engl J Med"},{"key":"R23-16-20210204","first-page":"476","article-title":". Thalidomide prevents donor corneal graft neovascularization in an alkali burn model of corneal angiogenesis.","volume":"52","author":"Abbas","year":"2002","journal-title":"J Pak Med Assoc"},{"key":"R24-16-20210204","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1056\/NEJM199512283332608","article-title":"Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis.","volume":"333","author":"Folkman","year":"1995","journal-title":"N Engl J Med"},{"key":"R25-16-20210204","doi-asserted-by":"crossref","first-page":"4236","DOI":"10.4049\/jimmunol.161.8.4236","article-title":". CC-3052: a water-soluble analog of thalidomide and potent inhibitor of activation-induced TNF-alpha production.","volume":"161","author":"Marriott","year":"1998","journal-title":"J Immunol"},{"key":"R26-16-20210204","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1097\/ICO.0b013e318241433b","article-title":"Treatment of corneal neovascularization by topical application of ascorbic acid in the rabbit model.","volume":"31","author":"Lee","year":"2012","journal-title":"Cornea"},{"key":"R27-16-20210204","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/ICO.0b013e318221ce99","article-title":". Clinical and histopathological outcomes of subconjunctival triamcinolone injection for the treatment of acute ocular alkali burn in rabbits.","volume":"31","author":"Saud","year":"2012","journal-title":"Cornea"},{"key":"R28-16-20210204","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.3109\/02713683.2011.601840","article-title":". The impact of subconjuctivally injected EGF and VEGF inhibitors on experimental corneal neovascularization in rat model.","volume":"36","author":"Sener","year":"2011","journal-title":"Curr Eye Res"},{"key":"R29-16-20210204","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1167\/iovs.10-5548","article-title":". Critical role of TNF--induced macrophage VEGF and iNOS production in the experimental corneal neovascularization.","volume":"53","author":"Lu","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R30-16-20210204","first-page":"448","article-title":". Comparison of the effects of bevacizumab and ranibizumab injection on corneal angiogenesis in an alkali burn induced model.","volume":"5","author":"Dursun","year":"2012","journal-title":"Int J Ophthalmol"},{"key":"R31-16-20210204","first-page":"2194","article-title":". Matrix metalloproteinases and metalloproteinase inhibitors in choroidal neovascular membranes.","volume":"39","author":"Steen","year":"1998","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R32-16-20210204","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0968-0004(97)01074-8","article-title":"Molecular mechanisms of blood vessel formation.","volume":"22","author":"Bussolino","year":"1997","journal-title":"Trends Biochem Sci"},{"key":"R33-16-20210204","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1126\/science.285.5425.245","article-title":". Pigment epithelium-derived factor: a potent inhibitor of angiogenesis.","volume":"285","author":"Dawson","year":"1999","journal-title":"Science"},{"key":"R35-16-20210204","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1093\/annonc\/mdh300","article-title":"Thalidomide in cancer medicine.","volume":"15","author":"Eleutherakis-Papaiakovou","year":"2004","journal-title":"Ann Oncol"},{"key":"R36-16-20210204","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1006\/exer.1997.0292","article-title":"Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization.","volume":"64","author":"Kenyon","year":"1997","journal-title":"Exp Eye Res"},{"key":"R37-16-20210204","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1073\/pnas.91.9.4082","article-title":". Thalidomide is an inhibitor of angiogenesis.","volume":"91","author":"DAmato","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R38-16-20210204","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1159\/000337137","article-title":". Potential inhibitory effect of LASSBio-596, a new thalidomide hybrid, on inflammatory corneal angiogenesis in rabbits.","volume":"48","author":"Ribeiro","year":"2012","journal-title":"Ophthalmic Res"},{"key":"R39-16-20210204","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1046\/j.1365-2249.2000.01117.x","article-title":". The thalidomide analogue CC-3052 inhibits HIV-1 and tumour necrosis factor-alpha (TNF-alpha) expression in acutely and chronically infected cells in vitro.","volume":"119","author":"La Maestra","year":"2000","journal-title":"Clin Exp Immunol"},{"key":"R40-16-20210204","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1046\/j.1365-2249.2000.01332.x","article-title":". Thalidomide analogue CC-3052 reduces HIV neutrophil apoptosis in vitro.","volume":"121","author":"Guckian","year":"2000","journal-title":"Clin Exp Immunol"},{"key":"R41-16-20210204","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.semcancer.2004.06.006","article-title":"Inflammation as a tumor promoter in cancer induction.","volume":"14","author":"Philip","year":"2004","journal-title":"Semin Cancer Biol"},{"key":"R42-16-20210204","first-page":"2510","article-title":". Inhibition of inflammatory corneal angiogenesis by TNP-470.","volume":"42","author":"Joussen","year":"2001","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R43-16-20210204","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s004170050106","article-title":". Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor.","volume":"236","author":"Kruse","year":"1998","journal-title":"Graefes Arch Clin Exp Ophthalmol"}],"container-title":["Cornea"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/ICO.0b013e318292a79d","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,2]],"date-time":"2023-07-02T06:32:26Z","timestamp":1688279546000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00003226-201308000-00016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":42,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/ico.0b013e318292a79d","relation":{},"ISSN":["0277-3740"],"issn-type":[{"value":"0277-3740","type":"print"}],"subject":[],"published":{"date-parts":[[2013,8]]}}}